Kinneret for Juvenile Rheumatoid Arthritis – pro
Anakinra (Kineret) is a biological drug used to treat rheumatoid arthritis. It is a recombinant human interleukin 1 receptor antagonist protein.
Kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs).
The American College of Rheumatology’s 2013 JIA treatment guidelines recommend anakinra as a first-line therapy for children with active systemic disease. The updated ACR recommendations also suggest using IL-inihibitors, including tocilizumab and canakinumab, when other drugs fail to improve symptoms.
JPardeo M et al, Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.Rheumatol. 2015 Aug;42(8):1523-7.
S. RIngold et al, 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Care Res (Hoboken). 2013 Oct; 65(10): 1551–1563.
Kinneret. Prescribing Information 2018